<DOC>
	<DOCNO>NCT01740713</DOCNO>
	<brief_summary>Deferiprone ( DFP ) extensively study oral iron chelator date . It authorise Europe 1999 treatment iron overload patient beta-thalassaemia major DFO contraindicate inadequate . Despite wide experience DFP limit experimental data available DFP child pharmacokinetic data child 6 year age . On basis exist data adult adolescent , DEEP-1 trial pharmacokinetic bridging model develop support dose selection child age less 6 year affected transfusion dependent haemoglobinopathy . The study consist two phase , namely experimental phase , patient receive single dose model phase , PK data obtain single dose patient &lt; 6 year age analyse conjunction historical PK data adult old child adolescent . The model-based analysis data obtain single dose enable assessment dose regimen require purpose accurate pharmacokinetic bridging . The ratio predict systemic exposure parameter ( AUC Cmax ) target population reference group use basis recommendation dose target population .</brief_summary>
	<brief_title>Pharmacokinetic Study Deferiprone Paediatric Patients</brief_title>
	<detailed_description>Deferiprone ( DFP ) investigate therapy child 1 month less 6 year age . The study multicenter randomise , single blind , single dose PK study . The patient randomise accord stratification scheme three different dose level use . Objectives : The primary objective study ass pharmacokinetics DFP paediatric patient age 1 month less 6 year . The secondary objective study : 1 . To identify dose level yield deferiprone exposure comparable adult define dose rationale child age 1 month less 6 year . 2 . To evaluate safety tolerability deferiprone single dose administration child age 1 month less 6 year . 3 . To evaluate effect demographic covariates DFP disposition estimate clearance distribution across population . Endpoints : The primary endpoint study pharmacokinetic included : - primary PK parameter : CL/F , Vd/F , Ka - secondary PK parameter : AUC , Cmax , Tmax , Css Cmin . Secondary endpoint assessment clinical safety tolerability . Methods : Twenty-three patient enrol 18 ( 9 male 9 female ) complete study . The patient administer three dose level ( 6 patient / dose ) : Dose level 1 : 8.3 mg/kg single dose ( every 8 h ) total daily dose 25mg/kg Dose level 2 : 16.7 mg/kg single dose ( every 8 h ) total daily dose 50 mg/kg Dose level 3 : 33.3 mg/kg single dose ( every 8 h ) total daily dose 100 mg/kg Blood sample PK analysis take 6 sampling time interval , different depend dose group : predose ; range 10 -20 min ; range 40-55min ; range 1.05-1.15 h ; range 1.25-5.30 h ; range 6-8h first dose administration . The concentration deferiprone determine validated HPLC method . A population PK model approach applied time course deferiprone concentration analyse Nonlinear mixed effect model NONMEM , version 7.2.0 . Model building include assessment influence relevant demographic covariates ( i.e : body weight , age , height ) disposition deferiprone . Using pharmacokinetic model develop paediatric population study conjunction model previously develop 55 adult subject , simulation perform evaluate drug exposure child 6 year age across standard thalassaemic adult population . Descriptive statistic use summarise adverse event , vital sign clinical lab data ( haematology , biochemistry virology ) Results : A one-compartment model first-order absorption find best describe disposition deferiprone . The choice three dose level enable assess linearity pharmacokinetic across dose range . The disposition parameter estimate pop-PK model include CL/F , V/F . In addition final model parameter estimate , secondary pharmacokinetic parameter derive base individual predict concentration vs. time profile summarise per dose level . Body weight found good predictor inter-individual difference population investigation . As expect known safety profile drug , Serious Adverse Events observe DEEP-1 PK Study . Based simulation analysis perform , similar exposure achieve adult child term AUC Css receive current dose regimen 75 100 mg/kg/day , considerable increase Cmax observe child compare adult population . However , exposure parameter relate clinical response rather Cmax . Indeed , simulation suggest dose regimen 25 mg/kg t.i.d . ( 75 mg/kg/day ) recommend child age 1 month &lt; 6 year , possibility titration 33.3 mg/kg t.i.d . ( 100 mg/kg/day ) , necessary .</detailed_description>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Patients chronic transfusional program receive least 150 ml/kg/year pack red blood cell ( correspond approximately 12 transfusion ) current treatment DFO , DFX , DFP ; age 1 month less 6 year ; Patients na√Øve chelation treatment receive less 150 ml/kg pack red blood cell ( correspond approximately 12 transfusion ) ferritin level &gt; 800 ng/mL , age 1 month less 6 year ; Patients meet transfusion criterion ( 150 ml/kg/year correspond approximately 12 transfusion ) know intolerance contraindication DFO And follow criterion apply : Patients affect hereditary haemoglobinopathy require chronic transfusion therapy include limited thalassaemia sickle cell disease Written inform consent obtain legal guardian patient 's behalf accordance national legislation . According his/her capability , patient 's informed assent collect Patient know intolerance contraindication trial treatment Patient Hb level less 8g/dl ( entry may delay value return normal ) Patient platelet count &lt; 100.000/mm3 absolute neutrophil count &lt; 1.500/mm3 ( entry may delay value return normal ) Patient evidence abnormal liver function ( ALT level &gt; 5 time upper normal limit six month precede enrolment ; entry may delay value return normal ) iron overload cause transfusional haemosiderosis severe heart dysfunction secondary iron overload define occurrence heart failure severe arrhythmia indicate cardiac T2* low 10 m , recent MRI data available , Patient serum creatinine level upper normal limit screening ; entry may delay value return normal . Serological evidence chronic hepatitis B ( presence HBe Ag , HBsAg , HBcAbIgM , absence HBsAb ) . History significant medical psychiatric disorder may impair compliance requirement protocol . The patient receive another investigational drug within 30 day prior study . Patient preexist condition surgical medical condition might significantly interfere normal gastrointestinal hepatic function could alter absorption , metabolism , and/or excretion study drug . Patient known history HIV seropositivity . Fever signs/symptoms infection 10 day drug administration ( treatment day ) Concomitant use iron chelators trivalent cationdependent medicinal product aluminiumbased antacid . Patient chronic condition allow suspension relate treatment start washout drug administer .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>chronic iron overload</keyword>
	<keyword>hereditary haemoglobinopathy</keyword>
	<keyword>beta thalassaemia major</keyword>
</DOC>